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Ubiquitin C-terminal hydrolase-L3 (Uch-L3), a deubiquitinating enzyme, is upregulated in bone
morphogenetic protein 2-induced osteoblast differentiation. The mechanism and role of Uch-L3
in the process of osteoblast differentiation is unknown. We found that Uch-L3 physically interacts
with Smad1 and dramatically decreases the amount of poly-ubiquitinated Smad1. Osteoblast differ-
entiation was enhanced in the C2C12 cells stably transfected with Uch-L3. Otherwise, the siRNA
knock-down of Uch-L3 resulted in the decrease of osteoblast differentiation. These results suggest
that Uch-L3 enhances osteoblast differentiation through the stabilization of Smad1 signaling. Thus,
Uch-L3 acts to ﬁne-tune the process of Smad1 activation.
Structured summary of protein interactions:
UCHL3 physically interacts with SMAD1 by anti tag coimmunoprecipitation (View interaction)
UCHL3 physically interacts with SMAD1 by anti bait coimmunoprecipitation (View interaction)
SMAD1 physically interacts with UCHL3 by anti tag coimmunoprecipitation (View interaction)
UCHL3 physically interacts with SMAD1 by anti tag coimmunoprecipitation (View interaction)
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The process of ubiquitination/deubiquitination is a pivotal
mechanism of controlling protein action in various biological pro-
cesses and diseases [1–5]. The loss of function in ubiquitin–protea-
some system-related proteins results in the development of
various diseases including neurodegenerative disease, cancers,
and osteoporosis [1,2,6–8]. Deubiquitination, the removal of cova-
lently attached ubiquitin from the target protein, is catalyzed by
deubiquitinating enzymes to regulate the abundance and/or func-
tional activity of target proteins. These enzymes consist of four
groups, ubiquitin C-terminal hydrolases (UCHs), ubiquitin-speciﬁc
proteases (USPs), otubain domain-containing proteins (OTUs), and
Machado-Joseph domain (Josephin domain)-containing proteins
(MJD) [9]. The UCHs family includes Uch-L1, Uch-L3, Uch-L5, and
BAP1. Uch-L3 is expressed in various tissues [10]. The Uch-L3 gene
is located on mouse chromosome 14 (human chromosome 13).
Bone morphogenetic proteins (BMPs) play important roles in
skeletal development and bone formation. In vivo bone formationchemical Societies. Published by E
iochemistry, School of Den-
-dong 2-ga, Daegu 700-422,is induced by recombinant human BMP2 and BMP7 [11]. BMP2 and
BMP7 initiate signal transduction by binding to BMP receptor type
I and II, and cause the phosphorylation and activation of Smad 1/5/
8. The activated Smads heterodimerize with Smad4 and translo-
cate from the cytosol to the nucleus leading to expression of the
down-stream target genes. In TGFb signaling, two known deubiq-
uitinating (DUB) enzymes, Usp9X (FAM) and Uch-L5 (Uch37) are
involved in the stability and activation of target proteins [12,13].
In Wnt/b-catenin signaling, Uch-L1 positively regulates the process
by the increased stability of b-catenin [14]. The regulation of ubiq-
uitination and/or deubiquitination is also critical in the regulation
of cellular metabolism [15–17].
The loss of Uch-L3 expression showed retinal degeneration,
skeletal muscle degeneration, and weakness of testis following
cryptorchid injury [18–20]. Two recent reports suggest a function
for Uch-L3 in obesity and insulin signaling [21,22]. Furthermore,
the induction of the stress response was observed in the mouse
embryonic ﬁbroblast (MEF) cells from Uch-L3 deﬁcient mice;
the MEF cells showed up-regulation of cleaved ATF6, Grp78,
and some HSPs and the accumulation of poly-ubiquitinated pro-
teins [23]. It suggests the defective role of Uch-L3’s deubiquitinat-
ing activity might cause the increase of poly-ubiquitination on
target proteins. Uch-L3 was also shown to be involved in onco-
genesis [24–26].lsevier B.V. All rights reserved.
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lator for identifying the speciﬁc targets in bone morphogenetic
protein (BMP) 2-induced osteoblast differentiation [27]. There is
limited information on the function of Uch-L3 in bone metabolism.
Therefore, the current study focuses on the function of Uch-L3 in
BMP2-induced osteoblast differentiation.2. Materials and methods
2.1. Cells, reagents and plasmids
The mouse premyoblast C2C12 cells and the human embryonic
kidney HEK293 cells were maintained as previously described
[28,29]. The primary osteoblast cells were isolated from mouse
long bone according to the previous reports [30,31]. The construct
of pCMV2-Flag-tagged Smad1 and pCI-neo-Flag-Uch-L3 were gifts
from Dr. T. Katagiri (Department of Biochemistry, School of
Dentistry, Showa University, Tokyo, Japan) and Dr. K. Wada
(Department of Degenerative Neurological Diseases, National
Institute of Neuroscience, Tokyo, Japan), respectively. The retroviral
expression vector for Uch-L3 plasmid22564 andpCMV5-HA-Smad1
plasmid 14956were purchased fromAddgene [32,33]. Anti-Uch-L3,
anti-Samd1, anti-phospho-Smad 1/5/8 antibodies were from Cell
Signaling (MA, USA) and anti-HA, anti-Flag, anti-b-actin antibodies,
and alkaline phosphatase staining kit were from Sigma–Aldrich
(MO, USA).
2.2. RNA isolation and real-time RT-PCR
The total RNA was extracted by TRIZOL reagent (Invitrogen, CA,
USA) according to the manufacturer’s instructions. The real-time
PCRwas performedwith the DNA Engine OPTICON 2 system (MJ re-
search, MA, USA) and Go Taq Flexi DNA polymerase (Promega, WI,
USA) used for PCR reactions as described previously [33,34]. The
sequences of primers used in this study are 50-TGAAGGTCAGACT-
GAGGCACC-30 and 50-AATTGGAAATGGTTTCCGTCC-30 for Uch-L3,
50-GATAACGAGATGCCACCAGAGG-30 and 50-TCCACGTCGGTTCTGT
TCTTC-30 for Alp, 50-TGCACCCAGATCCTATAGCC-30 and 50-CTCCATC
GTCATCATCATCG-30 for Opn, 50-GAGTCTGACAAAGCCTTCA-30 and
50-AGCCATACTGGTCTGATAG-30 for Oc, 50-ACAGCGGGCGAGGTG
GTACTTG-30 and 50-TCCGGTGGTCCCGACTTCAGA-30 for ID1, 50-GCC-
CAGCACCCAGC GACAA-30 and 50-CGGCACCTCCAGCCGGTC-30 for
Noggin, and 50-GGCATTGCTCTCAATGACAA-30 and 50-TGTGAGGGA-
GATGCTCAGTG-30 for Gapdh.
2.3. Recombinant retrovirus production and transduction into the cells
Uch-L3was overexpressed in C2C12 cells by retroviral transduc-
tion using previously described method [35]. Brieﬂy, the HEK 293
cells were co-transfected with the retroviral Uch-L3 vector, pGag,
and pVSV, and then incubated for 48 h. The viral supernatant were
collected and incubated in C2C12 cells. The cells were selected 24 h
after the transduction by puromycin (4 lg/ml) for 5 days.
2.4. siRNA-mediated knock-down of Uch-L3
The mouse Uch-L3 siRNA and scrambled siRNA (negative con-
trol) were purchased from Bioneer Co. (Daejeon, Korea). The du-
plex was transiently transfected into C2C12 cells with HiPerfect
transfection reagent (Qiagen, CA, USA) according to the manufac-
ture’s protocol. Brieﬂy, C2C12 cells were seeded on six-well plates.
Each siRNA (200 nM) was transfected and incubated for 24 h, and
then the media was changed before the treatment of BMP2
(100 ng/ml, jPC, Incheon, Korea). The cells were collected after
24 h for RNA isolation.2.5. Co-immunoprecipitation
The cells were lysed with a buffer containing 10 mM Tris,
200 mM NaCl, 5 mM MgCl2, 10 mM EDTA, 10% glycerol, and a pro-
tease inhibitor cocktail (Roche, Mannheim, Germany) [36]. The ly-
sates were immunoprecipitated with either anti-Flag antibody or
anti-HA antibody, and the eluents were loaded on a 12% SDS–PAGE
gel. The blots were incubated overnight at 4 C with either anti-HA
antibody or anti-Flag antibody. After washing in TBS containing
0.05% Tween 20, the blots were incubated for 1 h at room temper-
ature with anti-mouse IgG horseradish peroxidase-linked second-
ary antibody. The protein bands were visualized by ECL
(Amersharm Pharmacia Biotech, NJ, USA).
2.6. In vivo ubiquitination assay
The HEK 293 cells were transiently transfected with the plas-
mids, pcDNA-HA/Flag-Smad1, pcDNA-Flag/HA-Ub, and/or pcDNA-
Flag-Uch-L3. After 16 h, the transfected cells were treated with
the proteasome inhibitor MG-132 (10 lM) for an additional 8 h.
The cell lysates were immunoprecipitated with anti-HA antibody
overnight at 4 C. After 3 times washing, the eluents were immu-
noblotted against anti-Flag or Smad1 antibodies.
2.7. Alkaline phosphatase (ALP) staining
ALP staining was performed as previously reported [37]. Brieﬂy,
osteogenic transdifferentiation was induced in C2C12 cells for 24 h
with BMP2 stimulation. The cells were then washed with 1 PBS,
ﬁxed with 2% PFA, and stained for alkaline phosphatase.
2.8. Immunocytochemistry
The C2C12 cells were seeded on cover glass in six-well plate.
The mouse Uch-L3 siRNA and scrambled siRNA (negative control)
were transfected. After 24 h of transfection, the cells were treated
with BMP2 (100 ng/ml) for 3 h and ﬁxed in 4% paraformaldehyde
solution for 1 h. After the ﬁxation, the cells were incubated in the
freezer in the presence of ice-cold 100% EtOH. After the blocking
with 3% BSA, the anti-phospho Smad1 antibody (1:500) was incu-
bated overnight at 4 C. Then, the cells were incubated in the anti-
rabbit alexa-Fluor-555-conjugated secondary antibody (1:500) in
the dark. The counterstaining was performed with DAPI for visual-
ization of nuclei (Vector Lab., Burlingame, CA). The 1 PBS was
used in the washing steps (3 times) between steps. The photogra-
phy was taken by a ﬂuorescent microscope (Zeiss, Exton, PA).3. Results
3.1. The deubiquitinating enzyme Uch-L3 physically interacted with
Smad1
Ubiquitin C-terminal hydrolase L3 (Uch-L3) was found in our
previous proteomic study as a possible modulator sufﬁcient to
identify the speciﬁc targets in bone morphogenetic protein (BMP)
2-induced osteoblast differentiation [27]. To investigate the inter-
action between Uch-L3 and Smad1, HA-Smad1 and Flag-Uch-L3
plasmids were transfected into HEK 293 cells. Co-immunoprecipi-
tation (IP) was performed against HA-Smad1 using anti-HA anti-
body. Uch-L3 protein (Flag-Uch-L3) was detected in the eluent of
the immuno-complex by western blot using anti-Flag antibody
(Fig. 1A). Reciprocally, the co-IP against Flag-Uch-L3 demonstrated
that the eluent contained HA-Smad1 (Fig. 1B). Furthermore, it
wondered whether the endogenous Smad1 interacts with Uch-L3.
We determined the endogenous Uch-L3 levels in primary
Fig. 1. The physical interaction between Uch-L3 and Smad1. The expression vectors for HA-Smad1 and/or Flag-Uch-L3 (Flag-Uch-L3 and/or HA-Smad1) were transfected into
HEK293 cells. After 24 h, the transfectants were lysed and immunoprecipitated. (A) Co-immunoprecipitation (Co-IP) against HA-Smad1 using anti-HA antibody was
performed and the eluent was immunoblotted against Flag-Uch-L3 using anti-Flag antibody. (B) Co-IP against Flag-Uch-L3 using anti-Flag antibody was performed and the
eluent was immunoblotted against HA-Smad1 using anti-HA antibody. (C) Ten micrograms proteins of cell lysates were loaded on a 12% SDS–PAGE gel. The blot was
incubated with anti-Uch-L3 antibody or anti-b-actin antibody. Isolated RNAs from the cells were used for real-time RT-PCR analysis with Uch-L3 primers. The values of Uch-
L3 mRNA were normalized by Gapdh. Ob, primary osteoblast cells; Mc, MC3T3-E1 cells; C2, C2C12 cells. (D) The stable Uch-L3-C2C12 cells were established by retroviral
transduction of Uch-L3 (L3) or by mock transduction (M). Co-IP against Flag-HA-Uch-L3 using anti-Flag antibody was performed with the lysate from the stable cells and the
eluents were immunoblotted against anti-Smad1 antibody. (E) Co-IP against the endogenous Uch-L3 using anti-Uch-L3 antibody was conducted with the lysate from C2C12
cells and the eluent was immunoblotted against anti-Smad1 antibody. A normal rabbit IgG was used as a negative control for immunoprecipitation. The arrow indicates the
Smad1 band. HC indicates heavy chain of IgG, a non-speciﬁc band. Short exp.; short exposure, Long exp.; long exposure.
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cells, similar levels of Uch-L3 proteins (Fig. 1C, upper panels) and
mRNA levels (Fig. 1C, lower panels) were observed. Among them,
C2C12 cells were selected to make the Uch-L3 stable cells. As
shown in Fig. 1D, the endogenous Smad1 was also detected in
the immunoprecipitated complex of Uch-L3 (Flag-Uch-L3). Fur-
thermore, the endogenous Uch-L3 was also interacted with the
endogenous Smad1 in C2C12 cells as conﬁrmed by co-IP against
anti-Uch-L3 antibody and WB using anti-Smad1 antibody
(Fig. 1E). All of these results showed that Uch-L3 interacts with
Smad1.
3.2. The poly-ubiquitinated Smad1 was dramatically decreased by
Uch-L3
After conﬁrming the interaction between Smad1 and Uch-L3,
we tested whether the deubiquitinating activity of Uch-L3 is able
to affect the ubiquitination pattern of Smad1. After the transfection
of HA-Smad1 and Flag-Ub constructs with increasing amount of
Uch-L3 or without Uch-L3 plasmid into HEK 293 cells, the degree
of Smad1 ubiquitination was analyzed. The addition of Uch-L3 con-
struct showed the signiﬁcant deubiquitination of Smad1 by a dose-
dependent manner (Fig. 2A, left panel). In the presence of Uch-L3,
the amount of poly-ubiquitinated Smad1 was dramatically
diminished compared to the control (in the absence of Uch-L3).
Reciprocally, poly-ubiquitinated Smad1 was also detected in the
HA-labeled ubiquitin/ubiquitinated protein complex immunopre-
cipitated with HA-Ub by anti-HA antibody. In addition, the amount
of poly-ubiquitinated Smad1 was also decreased in the presence ofUch-L3 (Fig. 2B, top panel). These results suggest that Uch-L3 can
deubiquitinate the poly-ubiquitinated Smad1.
3.3. Uch-L3 enhances the differentiation of osteoblast
We then tested whether Uch-L3, a possible DUB enzyme of
Smad1, is able to accelerate the differentiation of osteoblast. The
efﬁcient stable expression of Uch-L3 was produced by the retrovi-
ral transduction onto C2C12 cells. The Uch-L3-expressing stable
cells were selected by puromycin for 5 days. After the selection,
we conﬁrmed the expression of exogenous Flag-HA-Uch-L3 from
the stable cell by Western blot (Fig. 3A). The activity of alkaline
phosphatase (ALP), a downstream molecule in Smad1 pathway,
was clearly enhanced as detected by ALP staining in Uch-L3
over-expressing cells compared to that in mock control cells
(Fig. 3B, upper panels). The enhanced ALP activity may be caused
by the deubiquitinating activity of Uch-L3 stabilizing Smad1.
Moreover, BMP2-induced stimulation further increased ALP activ-
ity in Uch-L3 over-expressing cells compared to control cells
(Fig. 3B, lower panels).
It is known that BMP2 activates Smad1 and induces the expres-
sion of the downstream genes. We checked the expression of some
downstream target genes: alkaline phosphatase (Alp), osteopontin
(Opn), osteocalcin (Oc), ID1, and Noggin. The induction of these
genes was conﬁrmed by real-time RT-PCR with BMP2 treatment
(100 ng/ml). The expressions of Opn, Alp, Oc, ID1, and Noggin were
higher in Uch-L3 stably-expressing cells compared to control cells
(Fig. 3C). These results of increased expression of differentiation
markers and down-stream target genes suggest that Uch-L3 may
Fig. 2. The reduction of ubiquitinated Smad1 by Uch-L3. The expression vectors for HA-Smad1 and Flag-Ubiquitin (Flag-Ub), or HA-Ubiquitin (HA-Ub) and Flag-Smad1 with/
without Flag-Uch-L3 were transfected into HEK293 cells. (A) The transfectants were lysed and incubated with anti-HA antibody for in vivo HA-Smad1 ubiquitination assay.
The eluent was immunoblotted with anti-Flag antibody. The numbers 1, 2, and 3 indicate the amount of Flag-Uch-L3 plasmid in lg, which was transfected into the cells. (B)
The lysates of transfectants were incubated with anti-HA antibody to capture HA-Ub conjugated proteins for in vivo ubiquitination assay. The eluent was immunoblotted
with anti-Smad1 antibody. Total lysates were also immunoblotted with anti-Flag antibody for the detection of Uch-L3 and Smad1. ‘[’ indicates the poly-ubiquitinated
proteins. Arrow indicates mono-ubiquitinated Smad1. HC indicates heavy chain of IgG.
Fig. 3. The effect of Uch-L3 over-expression on osteoblast differentiation. The stable C2C12 cells were established by retroviral transduction of Uch-L3 (L3) or by mock
transduction (M). (A) The C2C12 cells were lysed and immunoblotted with the indicated antibodies. (B) The stable C2C12 cells were treated with (+) or without () BMP2
(100 ng/ml) for 1 day. Alkaline phosphatase staining was performed on the cells. (C) The isolated RNA from the stable cells was reverse-transcribed and real-time PCR was
conducted with the primers for Opn, Alp, Oc, ID1, and Noggin. The relative values of each mRNA were normalized by Gapdh. The data are expressed as mean ± S.D. of three
different experiments. M, Mock control cells; L3, Uch-L3 stable cells.
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Smad1.
3.4. Delayed osteoblast differentiation by the reduction of Uch-L3
To determine the effect of Uch-L3 knock-down in osteoblast dif-
ferentiation, Uch-L3 speciﬁc siRNA was transfected into C2C12
cells. The expressions of Uch-L3 mRNA and protein after transfec-
tion were evaluated by real-time RT-PCR and immunoblotting
(Fig. 4A). We then checked the osteoblast differentiation markers
in the cells transfected with the Uch-L3 speciﬁc siRNA and thescrambled siRNA (negative control). The ALP staining was greatly
reduced in Uch-L3 knock-down cells compared to the scrambled
siRNA control cells (Fig. 4B). The mRNA expression levels of the
markers, Opn, Alp, and Oc were also reduced in the Uch-L3 siRNA
cells compared to the control cells (Fig. 4C). Furthermore, in the
Uch-L3 knock-down cells transfected with L3-siRNA, the level of
BMP2-induced phosphorylated Smad1 (pSmad1) was dramatically
reduced 3 h after BMP2 treatment (Fig. 4D). In the immunocyto-
chemical staining, the Uch-L3 knock-down cells showed the re-
duced expression of pSmad1 in the nucleus 3 h after BMP2
treatment, while the cells transfected with scrambled siRNA (Ctl)
Fig. 4. The effect of Uch-L3 knock-down on osteoblast differentiation. (A) The scrambled siRNA and Uch-L3 siRNA duplexes were transfected into C2C12 cells. The isolated
RNA from those cells was reverse-transcribed and the level of Uch-L3 expression was determined by real-time PCR (left panel). The cells were lysed and immunoblotted with
anti-Uch-L3 antibody (right panel). (B) The C2C12 cells transfected with scrambled siRNA or Uch-L3 siRNA for 24 h. The cells were treated with BMP2 (100 ng/ml) for 1 day
and stained by the alkaline phosphatase. (C) Real-time PCR was conducted using reverse-transcribed RNA and the primers of Opn, Alp, and Oc in the C2C12 cells transfected
with scrambled siRNA or Uch-L3 siRNA and treated with BMP2 (100 ng/ml) for 1 day. The relative values of each mRNA were normalized by Gapdh. The data are expressed as
mean ± S.D. of three different experiments. (D) After BMP2 treatment (100 ng/ml, 3 h) in the C2C12 cells transfected with either scrambled siRNA or Uch-L3 siRNA, the lysates
were immunoblotted against anti-pSmad1, Smad1, or Uch-L3 antibodies. b-Actin was used as a loading control. (E) The C2C12 cells transfected with either scrambled siRNA
or Uch-L3 siRNA were immunostained with anti-pSmad1 antibody. The cell nuclei were stained with a DAPI as a counterstaining. The ﬂuorescent images were captured by a
ﬂuorescent microscopy (magniﬁcation, 400). Ctl, the scrambled siRNA; si-L3, Uch-L3 speciﬁc siRNA.
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results suggest that the reduction of Uch-L3 decreases the active
pSmad1 signal and thus reduces the osteoblast differentiation.
4. Discussion
This study showed a novel function for Uch-L3 in osteoblast dif-
ferentiation induced by the regulation of BMP2 signaling. The
physical interaction between Uch-L3 and Smad1 was revealed.
The activity of deubiquitinating enzyme Uch-L3 dramatically
reduced the amount of ubiquitinated Smad1. In Uch-L3 stably-
expressing cells, the expression of osteoblast differentiation mark-
ers, speciﬁcally osteocalcin, osteopontin, and alkaline phosphatase,
was increased. In the Uch-l3 knock-down experiment, loss of Uch-
L3 resulted in reduced ALP staining and the reduced expression of
the markers. These results suggest that Uch-L3 plays a role as a
modulator in the BMP2-mediated osteoblastogenesis and thus
enhancing the differentiation of osteoblasts.
In our previous study, we reported elevated phosphorylation of
Uch-L3 in BMP2-induced osteoblast differentiation [27]. The loss of
Uch-L3 affects the accumulation of ubiquitinated proteins and the
induction of stress [23]. A defect of Uch-L3 also resulted in retinal
degeneration and neurodegeneration [6,18]. The up-regulation of
Uch-L3 expression was observed in breast invasive cancer and cer-
vical carcinoma [25,26]. Recent in vivo studies showed that the
Uch-L3 deﬁciency reduced insulin signaling and adipogenesis
[22]. However, there is no report on the possibility of Uch-L3 reg-
ulating osteoblast differentiation.
It has been reported that two proteins, Nedd8 and caseinolytic
peptidase B (CLPB), can interact with Uch-L3 [32,38]. The C-termi-
nal of Nedd8, an ubiquitin-like protein, is cleaved by Uch-L3. The
CLPB, a protein in disaggregating machines, was revealed as a part-
ner protein of Uch-L3 from a global proteomic approach. Inhibiting
Uch-L3 activity caused increased ubiquitination in epithelial so-
dium channel (ENaC), which is regulated by the ubiquitin E3 ligase
Nedd4-2 [39]. Although these studies highlight many importantfunctions of Uch-L3, there is little known about the role of Uch-
L3 in BMP signaling.
In TGFb signaling, two known deubiquitinating enzymes, Usp9X
(FAM) or Uch-L5 (Uch37) are known to act on the stability of the
target proteins, Smad4 or Smad7 and type I TGFb receptor, respec-
tively [12,13]. Recently, it was reported that Uch-L1 positively reg-
ulates the stability of b-Catenin in Wnt signaling [14]. As those
reports, UCH family members Uch-L1 and Uch-L5 which have
31–55% identity, function as deubiquitinating enzyme. However,
there is no information on the involvement of deubiquitinating en-
zymes in BMP signaling and/or the differentiation of osteoblasts. In
this study, it was found Smad1 is physically interacted with Uch-
L3, which deubiquitinates Smad1. That is, Smad1 poly-ubiquitina-
tion degrees were decreased by the forced expression of Uch-L3.
Furthermore, the forced expression of Uch-L3 promoted the osteo-
blast differentiation, and Uch-L3 knock-down showed reduced
differentiation.
This study shows a novel ﬁnding that osteoblast differentiation
could be regulated by Uch-L3, a deubiquitinating enzyme, through
the BMP2-induced Smad1 stabilization. Future studies using the
Uch-L3 knock-out mouse model will be necessary to understand
the in vivo functions of Uch-L3.
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